Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Thomas DörnerMartin KaulAntónia SzántóJui-Cheng TsengAthena S PapasIlona PylvaenaeinenMalika HanserNasri AbdallahAndrea GrioniAida Santos Da CostaEnrico FerreroPeter GergelyRainer HillenbrandAlexandre AvrameasBruno CenniRichard M SiegelPublished in: Annals of the rheumatic diseases (2023)
These data show preliminary efficacy and favourable safety of remibrutinib in a phase 2 trial for SjS.
Keyphrases
- placebo controlled
- double blind
- clinical trial
- tyrosine kinase
- phase ii
- phase iii
- electronic health record
- study protocol
- phase ii study
- big data
- case report
- disease activity
- anti inflammatory
- squamous cell carcinoma
- rheumatoid arthritis
- data analysis
- randomized controlled trial
- systemic lupus erythematosus
- machine learning
- artificial intelligence